Abstract
The inducibility of drug-metabolizing enzymes and transporters by numerous xenobiotics has become a vital issue to be considered in the drug development process. Activation of so-called orphan nuclear receptors has been identified to result in increased expression of these detoxifying systems and consequently altered drug levels in the human body. In order to anticipate such mechanisms already in early stages of drug design and to avoid dangerous drug-drug interactions, reliable in silico simulation tools are highly desirable. This review aims to give an introduction into induction of drug metabolism and transport and focuses on computer-assisted molecular modeling prediction techniques, on their applicability and limitations, on recent case studies, and on success stories.
Keywords: Nuclear receptors, in silico, molecular modeling, metabolism induction prediction
Current Topics in Medicinal Chemistry
Title: Predicting Drug Metabolism Induction In Silico
Volume: 6 Issue: 15
Author(s): Daniela Schuster, Theodora M. Steindl and Thierry Langer
Affiliation:
Keywords: Nuclear receptors, in silico, molecular modeling, metabolism induction prediction
Abstract: The inducibility of drug-metabolizing enzymes and transporters by numerous xenobiotics has become a vital issue to be considered in the drug development process. Activation of so-called orphan nuclear receptors has been identified to result in increased expression of these detoxifying systems and consequently altered drug levels in the human body. In order to anticipate such mechanisms already in early stages of drug design and to avoid dangerous drug-drug interactions, reliable in silico simulation tools are highly desirable. This review aims to give an introduction into induction of drug metabolism and transport and focuses on computer-assisted molecular modeling prediction techniques, on their applicability and limitations, on recent case studies, and on success stories.
Export Options
About this article
Cite this article as:
Schuster Daniela, Steindl M. Theodora and Langer Thierry, Predicting Drug Metabolism Induction In Silico, Current Topics in Medicinal Chemistry 2006; 6 (15) . https://dx.doi.org/10.2174/156802606778108924
DOI https://dx.doi.org/10.2174/156802606778108924 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms
Current Cardiology Reviews Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Truncated Human Cathepsin L, Encoded by a Novel Splice Variant, Exhibits Altered Subcellular Localization and Cytotoxicity
Protein & Peptide Letters Nanotechnology and Diabetic Wound Healing: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets NAD+, Sirtuins, and Cardiovascular Disease
Current Pharmaceutical Design RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Susceptibility Genes in Hypertension
Current Pharmaceutical Design Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology MicroRNAs in Atrial Fibrillation
Current Medicinal Chemistry